Use of the Vectra polyetherurethaneurea graft for dialysis access in HIV-positive patients with end-stage renal disease

A. Frederick Schild, Eduardo Perez, Erin Gillaspie, Asha R. Patel, Karlene Noicely, Neyton Baltodano

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The primary objective of this study was to establish the safety, efficacy, infection rate, and patency of the Vectra graft (polyetherurethaneurea) for dialysis access in patients diagnosed with human immunodeficiency virus (HIV) and end-stage renal disease. The Vectra graft has a unique self-sealing property; therefore we hypothesize that these patients will have fewer infections. A Vectra graft was implanted in 30 consecutive HIV-positive patients without sufficient veins for an autologous fistula. These surgeries were carried out over a 2.5-year period. Primary graft patency was 42% at 12 months and 3 (10%) of the grafts developed infection. This rate of graft infection was less (10% vs 45%) than both our prior experience and published reports using polytetrafluorothene bridge grafts. The unique self-sealing property of the Vectra graft minimizes the development of perigraft hematoma with repetitive needle cannulation and in the immunosuppressed HIV-positive patient, may account for the observed decrease in dialysis access infection.

Original languageEnglish
Pages (from-to)506-508
Number of pages3
JournalVascular and Endovascular Surgery
Volume41
Issue number6
DOIs
StatePublished - Dec 1 2008

Fingerprint

Chronic Kidney Failure
Dialysis
HIV
Transplants
Infection
liquid crystal polymer
Catheterization
Hematoma
Fistula
Needles
Veins
Safety

Keywords

  • End-stage renal disease
  • HIV
  • Infection
  • Patency
  • Thrombosis
  • Vascular access
  • Vectra

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Use of the Vectra polyetherurethaneurea graft for dialysis access in HIV-positive patients with end-stage renal disease. / Schild, A. Frederick; Perez, Eduardo; Gillaspie, Erin; Patel, Asha R.; Noicely, Karlene; Baltodano, Neyton.

In: Vascular and Endovascular Surgery, Vol. 41, No. 6, 01.12.2008, p. 506-508.

Research output: Contribution to journalArticle

Schild, A. Frederick ; Perez, Eduardo ; Gillaspie, Erin ; Patel, Asha R. ; Noicely, Karlene ; Baltodano, Neyton. / Use of the Vectra polyetherurethaneurea graft for dialysis access in HIV-positive patients with end-stage renal disease. In: Vascular and Endovascular Surgery. 2008 ; Vol. 41, No. 6. pp. 506-508.
@article{9217effe04894dffae0fc4f4a121aacc,
title = "Use of the Vectra polyetherurethaneurea graft for dialysis access in HIV-positive patients with end-stage renal disease",
abstract = "The primary objective of this study was to establish the safety, efficacy, infection rate, and patency of the Vectra graft (polyetherurethaneurea) for dialysis access in patients diagnosed with human immunodeficiency virus (HIV) and end-stage renal disease. The Vectra graft has a unique self-sealing property; therefore we hypothesize that these patients will have fewer infections. A Vectra graft was implanted in 30 consecutive HIV-positive patients without sufficient veins for an autologous fistula. These surgeries were carried out over a 2.5-year period. Primary graft patency was 42{\%} at 12 months and 3 (10{\%}) of the grafts developed infection. This rate of graft infection was less (10{\%} vs 45{\%}) than both our prior experience and published reports using polytetrafluorothene bridge grafts. The unique self-sealing property of the Vectra graft minimizes the development of perigraft hematoma with repetitive needle cannulation and in the immunosuppressed HIV-positive patient, may account for the observed decrease in dialysis access infection.",
keywords = "End-stage renal disease, HIV, Infection, Patency, Thrombosis, Vascular access, Vectra",
author = "Schild, {A. Frederick} and Eduardo Perez and Erin Gillaspie and Patel, {Asha R.} and Karlene Noicely and Neyton Baltodano",
year = "2008",
month = "12",
day = "1",
doi = "10.1177/1538574407308208",
language = "English",
volume = "41",
pages = "506--508",
journal = "Vascular and Endovascular Surgery",
issn = "1538-5744",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Use of the Vectra polyetherurethaneurea graft for dialysis access in HIV-positive patients with end-stage renal disease

AU - Schild, A. Frederick

AU - Perez, Eduardo

AU - Gillaspie, Erin

AU - Patel, Asha R.

AU - Noicely, Karlene

AU - Baltodano, Neyton

PY - 2008/12/1

Y1 - 2008/12/1

N2 - The primary objective of this study was to establish the safety, efficacy, infection rate, and patency of the Vectra graft (polyetherurethaneurea) for dialysis access in patients diagnosed with human immunodeficiency virus (HIV) and end-stage renal disease. The Vectra graft has a unique self-sealing property; therefore we hypothesize that these patients will have fewer infections. A Vectra graft was implanted in 30 consecutive HIV-positive patients without sufficient veins for an autologous fistula. These surgeries were carried out over a 2.5-year period. Primary graft patency was 42% at 12 months and 3 (10%) of the grafts developed infection. This rate of graft infection was less (10% vs 45%) than both our prior experience and published reports using polytetrafluorothene bridge grafts. The unique self-sealing property of the Vectra graft minimizes the development of perigraft hematoma with repetitive needle cannulation and in the immunosuppressed HIV-positive patient, may account for the observed decrease in dialysis access infection.

AB - The primary objective of this study was to establish the safety, efficacy, infection rate, and patency of the Vectra graft (polyetherurethaneurea) for dialysis access in patients diagnosed with human immunodeficiency virus (HIV) and end-stage renal disease. The Vectra graft has a unique self-sealing property; therefore we hypothesize that these patients will have fewer infections. A Vectra graft was implanted in 30 consecutive HIV-positive patients without sufficient veins for an autologous fistula. These surgeries were carried out over a 2.5-year period. Primary graft patency was 42% at 12 months and 3 (10%) of the grafts developed infection. This rate of graft infection was less (10% vs 45%) than both our prior experience and published reports using polytetrafluorothene bridge grafts. The unique self-sealing property of the Vectra graft minimizes the development of perigraft hematoma with repetitive needle cannulation and in the immunosuppressed HIV-positive patient, may account for the observed decrease in dialysis access infection.

KW - End-stage renal disease

KW - HIV

KW - Infection

KW - Patency

KW - Thrombosis

KW - Vascular access

KW - Vectra

UR - http://www.scopus.com/inward/record.url?scp=37249041632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37249041632&partnerID=8YFLogxK

U2 - 10.1177/1538574407308208

DO - 10.1177/1538574407308208

M3 - Article

VL - 41

SP - 506

EP - 508

JO - Vascular and Endovascular Surgery

JF - Vascular and Endovascular Surgery

SN - 1538-5744

IS - 6

ER -